In an ongoing Chinese phase I/II trial of HS-10365 (NCT05207787), 31 RET fusion + NSCLC patients with RET TKI-naivety were treated with HS-10365 at six doses (40 mg QD to 200 mg BID). This evidence concerns the gene RET and non-small cell lung carcinoma.